Literature DB >> 6593559

Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins.

N T Berlinger.   

Abstract

Monocytes from patients with head and neck cancer produce excessive PGE2 which seems to be associated with decreased lymphoproliferation in vitro. This may be a pathological exaggeration of a normal homeostatic mechanism. It is speculated that a stimulus for excessive PGE2 production could be immune complexes. Although PGE2 suppresses many important immune processes relevant for neoplasia, it can also have complex and diverse effects on tumor cells. Caution should be exercised with human trials of prostaglandin synthetase inhibitors such as indomethacin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6593559

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  8 in total

1.  Prognostic significance of plasma prostaglandin E concentration in patients with head and neck cancer.

Authors:  I Klapan; V Katić; F Culo; V Cuk
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Inhibition of tumor metastasis by carrageenan-induced granulomas.

Authors:  W J Kort; A M Bijma; I M Hekking
Journal:  Clin Exp Metastasis       Date:  1989 Jan-Feb       Impact factor: 5.150

3.  Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen.

Authors:  Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

4.  A short course of neoadjuvant IRX-2 induces changes in peripheral blood lymphocyte subsets of patients with head and neck squamous cell carcinoma.

Authors:  Theresa L Whiteside; Lisa H Butterfield; Paul H Naylor; James E Egan; John W Hadden; Lorraine Baltzer; Gregory T Wolf; Neil L Berinstein
Journal:  Cancer Immunol Immunother       Date:  2011-11-23       Impact factor: 6.968

5.  The in vitro development of cytotoxicity in response to granulocyte/macrophage-colony-stimulating factor or interferon gamma in the peripheral blood monocytes of patients with solid tumors: modulation by arachidonic acid metabolic inhibitors.

Authors:  D P Braun; K P Siziopikou; L C Casey; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 6.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

7.  Production of prostaglandin E by squamous carcinoma of the head and neck and adenocarcinoma of gastrointestinal tissue.

Authors:  F Culo; I Klapan; V Katić; T Kolak; B Bakula
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

Review 8.  IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers.

Authors:  Gregory T Wolf; Jeffrey S Moyer; Michael J Kaplan; Jason G Newman; James E Egan; Neil L Berinstein; Theresa L Whiteside
Journal:  Onco Targets Ther       Date:  2018-06-28       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.